2015
Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. European Journal Of Gynaecological Oncology 2015, 36: 260-7. PMID: 26189250.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPhosphoric Monoester HydrolasesPrognosisProportional Hazards ModelsPTEN PhosphohydrolaseTumor Suppressor Protein p53Young AdultConceptsAberrant p53 expressionOvarian cancerP53 expressionHazard ratioLoss of PTENOvarian tumorsOvarian cancer tissue samplesEndometrioid ovarian tumorsProtein expressionSurvival hazard ratioEpithelial ovarian tumorsPoor disease outcomePossible prognostic roleProportional hazards modelCancer tissue samplesPrognostic roleEndometrioid tumorsEndometrioid subtypePrognostic valuePoor prognosisSerous subtypeProtein immunohistochemistryDisease outcomeTissue microarrayHazards model
2014
Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma
Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, Shaheen NJ, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, Liu G, Corley DA, Blount PL, Fitzgerald RC, Whiteman DC, Wu AH, Reid BJ, Vaughan TL. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis 2014, 35: 2740-2747. PMID: 25280564, PMCID: PMC4247522, DOI: 10.1093/carcin/bgu207.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBarrett EsophagusCase-Control StudiesCyclin-Dependent Kinase Inhibitor p16Disease ProgressionEsophageal NeoplasmsFemaleFollow-Up StudiesGenome-Wide Association StudyHumansMaleMiddle AgedNeoplasm StagingPolymorphism, Single NucleotidePrognosisRisk FactorsTumor Suppressor Protein p53ConceptsEsophageal adenocarcinomaBarrett's esophagusSingle nucleotide polymorphismsRisk of EACPredictors of progressionGermline single nucleotide polymorphismsTP53 single nucleotide polymorphismsNucleotide polymorphismsCDKN2A polymorphismsEA tumorsFrequent somatic mutationsProspective cohortCDKN2A variantsMale genderRisk factorsReduced riskTumor suppressor gene CDKN2ACaucasian raceMiR-663bEA casesSomatic alterationsGermline variationAdenocarcinomaGenes CDKN2AEsophagus
2008
Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression
Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF, Chow WH. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes & Control 2008, 20: 361-368. PMID: 18989634, PMCID: PMC2726999, DOI: 10.1007/s10552-008-9250-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAnti-Inflammatory Agents, Non-SteroidalBody Mass IndexCarcinoma, Squamous CellCardiaCase-Control StudiesConfidence IntervalsEsophageal NeoplasmsGastroesophageal RefluxHumansImmunohistochemistryLogistic ModelsMiddle AgedMulticenter Studies as TopicOdds RatioPopulation SurveillanceRisk FactorsSmokingStomach NeoplasmsTumor Suppressor Protein p53United StatesConceptsBody mass indexNon-steroidal anti-inflammatory drugsGastroesophageal reflux diseaseRisk factorsP53 overexpressionGastric cancerCigarette smokingReflux diseaseMass indexNon-steroidal anti-inflammatory drug useTumor subtypesPopulation-based case-control studyAnti-inflammatory drug useNon-cardia gastric adenocarcinomaGastro-esophageal reflux diseaseLarger body mass indexNon-cardia gastric cancerEsophageal squamous cell carcinomaTumor p53 overexpressionRisk factor profileSquamous cell carcinomaRisk of subtypesCase-control studyAnti-inflammatory drugsP53 protein overexpression
2007
Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma
Vaninetti NM, Geldenhuys L, Porter GA, Risch H, Hainaut P, Guernsey DL, Casson AG. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Molecular Carcinogenesis 2007, 47: 275-285. PMID: 17849424, DOI: 10.1002/mc.20382.Peer-Reviewed Original ResearchConceptsInducible nitric oxide synthaseINOS mRNA expressionEsophageal adenocarcinomaNitric oxide synthaseP53 mutationsNitric oxideBarrett's esophagusOxide synthaseMRNA expressionEndogenous p53 mutationsGastroesophageal reflux diseaseActive inflammatory processPrimary esophageal adenocarcinomaPotential causative factorsReflux diseaseGastrointestinal malignanciesChronic inflammationINOS overexpressionEsophageal malignancyInflammatory processNormal epitheliumHuman premalignantEsophageal epitheliumMolecular pathogenesisSignificant association
1999
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer R, Shaw P, Verheijen R, Ryan A, Berchuck A, Ponder B, Risch H, McLaughlin J, Narod S, Menko F, Kenemans P, Jacobs I. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. Journal Of Clinical Pathology 1999, 52: 372. PMID: 10560359, PMCID: PMC1023075, DOI: 10.1136/jcp.52.5.372.Peer-Reviewed Original ResearchMeSH KeywordsBRCA2 ProteinFemaleGenes, BRCA1Germ-Line MutationHumansNeoplasm ProteinsNeoplastic Syndromes, HereditaryOvarian NeoplasmsTranscription FactorsTumor Suppressor Protein p53ConceptsOvarian cancer casesBRCA2 germline mutationsHereditary ovarian cancerOvarian cancerCancer casesP53 accumulationGermline mutationsSomatic genetic eventsInvasive ovarian cancer casesBRCA2 germline mutation carriersOvarian cancer patientsP53 proteinGermline mutation carriersGenetic eventsRole of p53Cancer patientsAntigen retrieval techniqueBRCA mutationsBRCA2 mutationsStudy groupMutation carriersP53 alterationsP53 immunohistochemistryGermline BRCA1Positive cases
1997
Re: Relationship Between Lifetime Ovulatory Cycles and Overexpression of Mutant p53 in Epithelial Ovarian Cancer
Risch H. Re: Relationship Between Lifetime Ovulatory Cycles and Overexpression of Mutant p53 in Epithelial Ovarian Cancer. Journal Of The National Cancer Institute 1997, 89: 1726-1727. PMID: 9390546, DOI: 10.1093/jnci/89.22.1726-a.Peer-Reviewed Original Research